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A comprehensive knowledge of the platelet prote-
ome is necessary for understanding thrombosis
and for envisioning antiplatelet therapies. To dis-
cover other biochemical pathways in human plate-
lets, we screened platelets with a carbamate library
designed to interrogate the serine hydrolase subpro-
teome and used competitive activity-based protein
profiling to map the targets of active carbamates.
We identified an inhibitor that targets arylacetamide
deacetylase-like 1 (AADACL1), a lipid deacetylase
originally identified in invasive cancers. Using this
compound, along with highly selective second-gen-
eration inhibitors of AADACL1, metabolomics, and
RNA interference, we show that AADACL1 regulates
platelet aggregation, thrombus growth, RAP1 and
PKC activation, lipid metabolism, and fibrinogen
binding to platelets and megakaryocytes. These
data provide evidence that AADACL1 regulates
platelet and megakaryocyte activation and highlight
the value of this chemoproteomic strategy for target
discovery in platelets.
INTRODUCTION
Human platelets are essential mediators of both hemostasis and
thrombosis. Endogenous signaling molecules and pathways
have been identified that directly contribute to essential platelet
functions including activation of the allbb3 integrin, cytoskeletal
reorganization during shape change, spreading, secretion of
intracellular granules, and homotypic cell-cell interactions (Shat-
til et al., 2010). Recurrent themes have emerged from the eluci-
dation of these signaling pathways, especially those that utilize
G protein-coupled receptors (GPCRs) such as thrombin and
ADP receptors or immunoglobulin-like receptors such as glyco-
protein VI (GPVI). Signals emanating from these receptors thatChemistry & Biology 20, 1125–113lead to the activation of allbb3 are termed ‘‘inside-out’’ (Watson
et al., 2005; Coughlin, 2005). These pathways share common
molecular components, second messengers, and integrin bind-
ing proteins and exhibit multiple overlapping nodes and feed-
back loops.
Knowledge of these platelet signaling pathways has slowly
facilitated the development of modern antiplatelet therapies in-
tended to prevent thrombus formation; however, to more rapidly
realize the potential of the platelet proteome, techniques that
survey not only the expression, but also the activity of multiple
proteins are required. One such proteomic technique called
activity-based protein profiling (ABPP) can simultaneously
detect large numbers of enzyme activities generally within the
same enzyme family (Barglow and Cravatt, 2007; Cravatt et al.,
2008; Paulick and Bogyo, 2008). A powerful extension of ABPP
known as competitive ABPP can actually identify enzymes
from complex cell or tissue proteomes and enable development
of selective inhibitors for these enzymes in vitro and in vivo, even
if substrate specificities are unknown. Competitive ABPP can
also be coupled to libraries of small molecules (e.g., carbamates)
to facilitate inhibitor or lead compound discovery (Li et al., 2007).
Competitive ABPP is usually applied to cell-free proteomes
but has never been applied to platelets in any capacity for any
enzyme family. This approach is especially suitable for broadly
examining biochemical pathways in the anucleate platelet, a
cell type that is resistant to many genomic approaches. Here
we screened live human platelets via a combination of carba-
mate profiling and competitive ABPPwith the goal of discovering
enzymes that positively influence signaling pathways leading to
allbb3 activation. To maximize our chances of success, we
targeted the serine hydrolase superfamily because of its large
size, estimated to represent 1% of the proteome, and its sensi-
tivity to well-characterized carbamate probes. We identified a
chlorinated phenyl carbamate (WWL91) that blocks fibrinogen
binding to activated platelets and identified its endogenous
enzyme targets as arylacetamide deacetylase-like 1 (AADACL1,
also known as KIAA1363 or NCEH1), a microsomal lipid hydro-
lase and acylpeptide hydrolase (APEH), a recently described
cytosolic hydrolase that cleaves acetylated peptides in T cells
(Adibekian et al., 2012; Jessani et al., 2002; Sekiya et al.,4, September 19, 2013 ª2013 Elsevier Ltd All rights reserved 1125
Figure 1. Inhibitor Discovery via Carbamate
Profiling of Human Platelets
(A) Gel-filtered human platelets were treated with
120 distinct carbamates (25 mM) for 30 min before
stimulation with 10 mM TRAP or not (NA, no
agonist). Mean fluorescence intensity of Fg bind-
ing and P-selectin exposure were measured by
flow cytometry and normalized to a TRAP-treated
positive control set at 100% (NC, no carbamate
plus 0.5% DMSO). Inhibitory carbamates are
shown in decreasing potency ranging from 81 ±
3.1% to 67 ± 9.4% inhibition; 40, 71, and 14 are
negative controls. Data represent the means ±
SEM (n > 2).
(B) Platelets were pretreated with 0.5% DMSO
vehicle control, 10 mM WWL91-urea, or 10 mM
WWL91 for 30 min before the addition of 10 mg/ml
type I collagen to stimulate aggregation, indicated
by an upward trace (y axis) over time (x axis).
Similar results were obtained with TRAP.
(C) Aggregation traces represented in (B) were
averaged and presented as means ± SEM.
WWL91-urea was statistically indistinguishable
from vehicle control, but WWL91 inhibited aggre-
gation by 82 ± 8.2% (25 mM WWL91, *p < 0.02,
**p < 0.001, n = 5).
(D) Platelets were treated with 0.25% DMSO or 25 mMWWL91 for 30 min and prepared for competitive ABPP as described in Experimental Procedures. Shown
are spectral counts (means ± SEM) of serine hydrolases in decreasing order of abundance. WWL91 treatment significantly reduced spectral counts for AADACL1
only (*p < 0.002 for AADACL1, p = 0.06 for APEH, n = 2).
See also Figure S1.
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AADACL1 Promotes Platelet Activation2009). The inhibitory effects of WWL91 in platelets could not be
attributed to APEH, but instead depended on AADACL1.
Inhibition of AADACL1 activity with a variety of agents blocked
platelet aggregation in response to multiple agonists; impaired
inside-out signaling to allbb3 in both human platelets and their
precursors, megakaryocytes; abolished synthesis of certain
ether lipids; and blocked activation of the small GTPase RAP1
and protein kinase C (PKC). Furthermore, inhibition of AADACL1
by RNA interference downregulated inside-out signaling to
allbb3 in a differentiated megakaryocytic cell line. These data
represent an initial report of AADACL1 protein expression in
platelets and megakaryocytes and demonstrate AADACL1-
dependent regulation of these cell types.
RESULTS
Carbamate Screening of Platelets
Gel-purified human platelets were profiled with a 120-member
carbamate library (Li et al., 2007) to identify compounds that
antagonized allbb3 activation. Platelets were pretreated sepa-
rately with each carbamate before agonist addition and analyzed
by flow cytometry for fibrinogen (Fg) binding as a measure of
allbb3 activation and for surface-exposed P-selectin as a mea-
sure of a-granule secretion. Of the entire library, 12 carbamates
strongly inhibited Fg binding and P-selectin exposure in
response to thrombin receptor-activating peptide (TRAP; Fig-
ure 1A). No inhibitors selectively blocked Fg binding without
also blocking surface accumulation of P-selectin. Inhibition
ranged from 61% to 81% and was not caused by membrane
permeability or cell lysis as measured by lactate dehydrogenase
(LDH) activity in supernatants from platelets treated with carba-
mates or dimethyl sulfoxide (DMSO; Figure S1 available online).1126 Chemistry & Biology 20, 1125–1134, September 19, 2013 ª201We next evaluated the selectivity profiles of the five most
efficacious carbamates via gel-based competitive ABPP using
fluorophosphonate-rhodamine (FP-Rh) to depict serine hydro-
lase activities. Only WWL91 visibly inhibited serine hydrolases
by gel fluorography (data not shown) and for this reason, we
focused on WWL91 for subsequent experiments. To confirm
thatWWL91 inhibition of platelet aggregation was due to specific
blockade of serine hydrolase activity, we synthesized a nonhy-
drolyzable derivative of WWL91 (WWL91-urea) by substituting
the carbamate reactive group with a urea group, rendering this
compound resistant to nucleophilic attack by serine residues
(Figures 1B, 1C, and S1A). As expected, WWL91-urea was inert
at concentrations of WWL91 that almost completely blocked
platelet aggregation, which provided a rationale for the pursuit
of the endogenous platelet target(s) of WWL91 using more
sensitive mass spectrometry (MS)-based methods.
Platelet Targets of Carbamate WWL91
Because carbamate profiling had revealed WWL91 as a rela-
tively selective serine hydrolase inhibitor in platelets, we sought
to identify its endogenous target(s) using FP-biotin and com-
petitive ABPP-MudPIT, a more sensitive, solution phase varia-
tion of the gel-based method mentioned previously (Jessani
et al., 2005). Following WWL91 pretreatment of intact platelets,
platelets were lysed and reacted with FP-biotin to enrich for
active serine hydrolases not inhibited by WWL91; hydrolases
bound to FP-biotin were identified and quantitated by tandem
mass spectroscopy. At least 14 serine hydrolases were repro-
ducibly detected with this method in human platelets, some of
which have not been described as endogenous platelet pro-
teins. Figure 1D shows a core list of serine hydrolases detected
in DMSO- or WWL91-treated human platelets in descending3 Elsevier Ltd All rights reserved
Figure 2. The Selective AADACL1 Inhibitor,
JW480, Blocks Platelet and Megakaryocyte
Functions
(A–D) Human platelets were pretreated with vary-
ing concentrations of JW480 or DMSO (0.5% for
all experiments) for 30 min and warmed to 37C
before initiation of aggregation with 500 ng/ml
collagen (A), 400 nMU46619 (B), 10 mMADP (C), or
24–187 nM g-thrombin (D). JW480 inhibited
collagen-dependent aggregation with an IC50 of
2.2 mM (*p < 0.004 for 5 mM JW480, **p < < 0.001
for 10–20 mM JW480 all versus DMSO, n = 7) and
an IC50 of 5.6 mM for U46619-dependent aggre-
gation (*p < 0.01 for 20 mM JW480 versus DMSO,
n = 6). JW480 also blocked ADP-dependent ag-
gregation (*p < 0.01 for 20 mM JW480 versus
DMSO, n = 3). (D) Platelets were isolated using a
wash protocol prior to treatment with 0, 5, 10, or
20 mM JW480 and stimulated with 24, 47, 94, or
187 nM g-thrombin. JW480 significantly inhibited
g-thrombin-dependent aggregation (*p < 0.02 for
5–20 mM JW480 at 24 nM g-thrombin and for
20 mM JW480 at 47 nM g-thrombin). Data
are means from six experiments (47–94 nM
g-thrombin), three experiments (187 nM) and two
experiments for 24 nM due to the lack of response
from some donors at this low concentration.
(E) Platelets were treated as in (D) before mea-
surement of Fg binding by flow cytometry. JW480
significantly inhibited Fg binding to activated platelets by 55 ± 7.2% at 20 mM versus DMSO at 47 nM g-thrombin (*p < 0.05, **p < 0.004, n = 4).
(F) Primary megakaryocytes (Foulks et al., 2009) were pretreated with 5 mM JW480, 50 mM benzil, or vehicle controls prior to stimulation with thrombin (0.01
units/ml) and Fg binding to integrin allb-expressing cells was detected via flow cytometry. JW480 significantly inhibited Fg binding by 51 ± 13% (*p < 0.05, n = 4).
All data represent means ± SEM.
See also Figures S2 and S6.
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AADACL1 Promotes Platelet Activationorder of peptide count. WWL91 competed with FP-biotin and
reduced spectral counts for two enzymes: arylacetamide de-
acetylase-like 1 (AADACL1) and acylpeptide hydrolase
(APEH). Because mRNA transcripts of both enzymes have
been reported in human platelets and megakaryocytes (Rowley
et al., 2011), we confirmed protein and mRNA expression of
AADACL1 in these cells with western blotting and next-
generation RNA sequencing (Figures S3A and S3C). Interest-
ingly, neither AADACL1 protein nor mRNA was detected in
mouse platelets, which precludes traditional mouse model sys-
tems for studying the role of AADACL1 in thrombosis (Fig-
ure S3B; Rowley et al., 2011). These expression data coupled
with the inhibition of platelet functions observed with WWL91
formed the basis of our initial hypothesis that one or both of
these enzymes are important regulators of human platelet
activation.
AADACL1 Is Important for Platelet Aggregation
We first assessed the role of AADACL1 in human platelet func-
tion because selective carbamate inhibitors that block the cata-
lytic activity of AADACL1 have been developed (Chang et al.,
2011; Chiang et al., 2006). We pretreated platelets with the
most selective and potent inhibitor of AADACL1 currently
developed, JW480 (Chang et al., 2011), and stimulated human
platelets with threshold concentrations of various agonists to
calculate half-maximal inhibitory concentration (IC50) values for
JW480, which allowed us to evaluate the relative sensitivities
of platelet signaling pathways to AADACL1 inhibition. JW480Chemistry & Biology 20, 1125–113dose-dependently inhibited aggregation in response to collagen
(500 ng/ml) with an IC50 of 2.2 mM, having effects at concentra-
tions as low as 1 mM (Figure 2A). The two parent carbamates
used to synthesize JW480, JW147 and JW148, also inhibited
aggregation in response to collagen, but with slightly less po-
tency (data not shown). Because collagen can stimulate the
release of secondary agonists such as thromboxane A2 (TxA2)
and ADP, we also tested the ability of JW480 to block platelet ag-
gregation downstream of a stable TxA2mimetic, U46619. JW480
blocked aggregation in response to U46619 with an IC50 of
5.6 mM (Figure 2B). Although not statistically different from the
inhibition of collagen-stimulated aggregation, JW480 appeared
to inhibit U46619-mediated aggregation less effectively.
JW480 also blocked ADP-dependent aggregation, but less
potently than either collagen- or U46619-mediated aggregation
(Figure 2C, IC50 30 mM). JW480 was much less effective and
variable in its ability to inhibit aggregation stimulated by the
more powerful agonist, g-thrombin. JW480 inhibited aggrega-
tion of platelets from two donors that responded to a low
threshold concentration of g-thrombin (24 nM, Figure 2D). How-
ever, platelets from four other donors only responded to higher
concentrations of g-thrombin (R 47 nM) and were not inhibited
by JW480 with one exception (47 nM g-thrombin with 20 mM
JW480). This relatively weak effect on thrombin signaling pre-
vented accurate calculation of IC50 values, but suggests that
AADACL1 regulates a common molecular pathway used by
multiple platelet agonists including collagen, TxA2, ADP, and
possibly thrombin.4, September 19, 2013 ª2013 Elsevier Ltd All rights reserved 1127
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AADACL1 Promotes Platelet ActivationIn addition to AADACL1, JW480 blocks murine carboxylester-
ase 1 in brain tissue extracts (Chang et al., 2011). Therefore, to
assess carboxylesterases as potential targets of JW480 in
human platelets, we pretreated platelets with benzil, an inhibitor
of both hCES1 and hiCE, the two main isoforms of human car-
boxylesterase (Hyatt et al., 2006). At concentrations at or below
20 mM, benzil did not block platelet aggregation (Figure S2C),
whereas the same concentrations of benzil abolished partially
purified hCES1 activity (Figure S2D). Similarly, benzil did not
affect Fg binding to megakaryocytes (Figure 2F), demonstrating
that the inhibitory effects of JW480 in platelets and megakaryo-
cytes are most likely independent of carboxylesterases.
Because competitive ABPP implicated APEH in addition to
AADACL1 as a platelet target of WWL91, we also tested a small
molecule inhibitor of APEH, AA74-1, for its ability to affect
platelet aggregation. Human platelets treated with AA74-1
(500 nM to 50 mM) were not significantly inhibited in their aggre-
gation response to collagen (Figures S2A andS2B), which further
strengthens our hypothesis that the predominant target of
WWL91 identified in our initial carbamate profiling efforts is
AADACL1 and that JW480 disrupts aggregation by specifically
targeting this hydrolase in human platelets.
AADACL1 Regulates Inside-Out Platelet Signaling
Platelet aggregation reflects a complex network of extracellular
and intracellular signals, including bidirectional signals leading
to and from the allbb3 integrin. Signals leading to the activation
of allbb3 for example are termed ‘‘inside-out’’ (Shattil et al.,
2010). Because WWL91 blocked inside-out signals leading to
allbb3 activation and granule release, we reasoned that JW480
might also block these events. We used g-thrombin as an
agonist instead of TRAP or collagen due to its greater potency
as an activator of allbb3. In the absence of JW480, g-thrombin
induced a dose-dependent increase in Fg binding to platelets
(Figure 2E). In the presence of JW480, Fg binding was inhibited
at all g-thrombin concentrations tested but was maximally
reduced by 55% (47 nM g-thrombin and 20 mM JW480). As ex-
pected, g-thrombin-induced Fg binding was inhibited more
readily by JW480 than g-thrombin-induced aggregation. This
probably reflects (1) the fact that significant inhibition of platelet
aggregation requires R80% blockade of fibrinogen receptor
(allbb3) occupancy, and (2) the extent to which allbb3 is acti-
vated in the two assays, with aggregation involving additional
feedback loops to reinforce activation (Mascelli et al., 1998).
To determine whether AADACL1 regulates inside-out
signaling in megakaryocytes, we utilized primary megakaryo-
cytes differentiated in vitro from human cord blood progenitors
(Foulks et al., 2009). As with platelets, we pretreatedmegakaryo-
cytes with JW480 and measured Fg binding by flow cytometry.
JW480 blocked Fg binding to thrombin-stimulated megakaryo-
cytes by 51% (Figure 2F), suggesting that AADACL1 participates
in both platelet and megakaryocyte inside-out signaling.
As an additional control for JW480, wemeasured Fg binding to
both Aadacl1-deficient and heterozygous murine platelets,
neither of which express AADACL1 (Figures S3B and S3C).
JW480 did not inhibit g-thrombin-stimulated Fg binding to
murine platelets (Figure S6), further demonstrating JW480
selectivity. This also excludes the possibility that JW480 directly
interferes with allbb3 ligand binding.1128 Chemistry & Biology 20, 1125–1134, September 19, 2013 ª201AADACL1 Contributes to Thrombus Formation Ex Vivo
Although our data clearly implicate AADACL1 as a regulator of
platelet activation, its role in thrombus formation under physio-
logic shear conditions had not been addressed. Because this
enzyme is not expressed in mouse platelets, we were unable
to use mouse models of thrombosis (Figure S3; Rowley et al.,
2011). Furthermore, JW480 is less active in human plasma or
whole blood presumably due to decreased bioavailability result-
ing from binding to serum proteins such as albumin. To circum-
vent these issues, we treated purified human platelets with
JW480 or DMSO and introduced them into platelet-depleted
mouse blood to study the role of AADACL1 in thrombosis in a
microfluidic flow chamber (see Experimental Procedures). This
method prevents JW480 exposure to other cell types such as
neutrophils while allowing maximal JW480-dependent inhibition
of platelets. At an arterial flow rate of 1,600 s1, human control
platelets adhered quickly and coalesced into multiple tear-
shaped thrombi beginning at approximately 1 minute after onset
of blood flow, demonstrating the feasibility of the assay (Fig-
ure 3A). Three-dimensional (3D) thrombus growth was evident
with video microscopy as increased cumulative fluorescence in-
tensity over time. In contrast, JW480 dose-dependently
impaired 3D growth (Figures 3A and 3B). At 10 mM JW480, 3D
growth was reduced but detectable as isolated islands of fluo-
rescence that exhibited 52% less fluorescence intensity than
control. At a higher dose of JW480 (25 mM), 3D growth was
dramatically inhibited (77%) as illustrated by the lack of intense
thrombi and the attenuated increase in fluorescence over time.
The aIIbb3 antagonist, eptifibatide (Phillips and Scarborough,
1997), was used as a positive control; eptifibatide-treated plate-
lets did not form thrombi (87% inhibition), but adhered as a
monolayer with no detectable platelet-platelet interactions.
Thus, high concentrations of JW480 inhibit thrombus formation
almost as effectively as a potent aIIbb3 antagonist. Importantly,
JW480 did not significantly affect platelet adhesion to collagen
under these conditions (data not shown), which demonstrates
that collagen binding to its receptors, GPVI and a2b1, was intact
and that JW480 effects can be attributed to defective thrombi
growth due to reduced inside-out signaling to aIIbb3 via these
receptors.
AADACL1 Knockdown Decreases allbb3 Activation in
CMK11-5 Cells
We sought to independently confirm the importance of
AADACL1 in aIIbb3 activation in response to collagen receptor
signaling using RNA interference (RNAi) in a megakaryocytic
cell line, CMK11-5. These cells efficiently perform RNAi, express
aIIbb3, and reportedly respond to agonists such as PMA and
thrombin (Tadokoro et al., 2011), but not ADP, collagen, or con-
vulxin, a snake toxin that binds and potently activates GPVI. To
achieve responsiveness to either collagen or convulxin, we
developed a 7-day differentiation protocol (see Experimental
Procedures) that stimulated a dramatic increase in aIIbb3 and
GPVI surface levels (Figure S4; Chen and Kahn, 2003). While
these more differentiated CMK11-5 cells still responded poorly
to collagen, they responded strongly to convulxin, with an
11-fold activation of aIIbb3-mediated Fg binding (Figure 4C).
Lack of collagen sensitivity may be due to the complex interplay
between the collagen receptors GPVI and a2b1, inadequate3 Elsevier Ltd All rights reserved
Figure 3. AADACL1 Inhibition Attenuates Thrombus Formation
Washed human platelets were treated with 10 mM or 25 mM JW480, 10 mM eptifibatide, or 0.25% DMSO and mixed with platelet-depleted mouse blood (see
Experimental Procedures). Blood was perfused over collagen at a flow rate of 1,600 s1 and thrombus formation was monitored by video microscopy at one
second intervals.
(A) Representative images of thrombi are shown. Note the teardrop morphology of rapidly forming thrombi in DMSO-treated controls and the lack of thrombus
growth in platelets treated with JW480 or eptifibatide. Scale bar is 10microns and images were extracted frommovies at 5 (DMSO and 25 mMJW480) or 7 (10 mM
JW480 and eptifibatide) min.
(B) Kinetics of thrombus growth are shown for the conditions depicted in (A). Data are presented as normalized fluorescence intensity over time. Pretreatmentwith
JW480 or eptifibatide significantly reduced thrombus growth compared to DMSO (52 ± 16% for 10 mM JW480, *p < < 0.001; 77 ± 2.5% for 25 mM JW480, *p < <
0.001; 87 ± 5.8% for eptifibatide, *p < < 0.001; means ± SEM, n = 4).
See also Figure S3.
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AADACL1 Promotes Platelet Activationsurface density of these receptors or lack of appropriate environ-
mental cues. Nevertheless, convulxin-mediated activation in
CMK11-5 cells has not been described previously.
During the differentiation process, we transfected CMK11-5
cells with AADACL1-specific small interfering RNA (siRNA) and
reduced AADACL1 protein levels by at least 90% compared to
two distinct control siRNAs (Figure 4A). Depletion of AADACL1
did not block differentiation of CMK11-5 cells as judged by
aIIbb3 surface expression (Figure 4B), but did reduce Fg binding
in response to convulxin by 41% compared to control siRNA-
transfected cells (Figure 4C). Fg binding to these cells was
aIIbb3-dependent because 1 mM RGD peptide or 9 mM eptifiba-
tide blocked Fg binding by 96% and 77%, respectively (Fig-
ure 4C). These data provide key genetic evidence that AADACL1
regulates inside-out signals leading to aIIbb3 activation.
Treatment of CMK11-5 cells with JW480 (10 mM) also reduced
Fg binding in response to convulxin by 50% (Figure 4D). This
inhibition was similar to the observed effects of JW480 on Fg
binding to primary megakaryocytes, again indicating that
AADACL1-dependent inside-out signaling pathways are pre-
served in CMK11-5 cells and that AADACL1 is required forChemistry & Biology 20, 1125–113maximal output of these pathways in response to certain ago-
nists in megakaryocytes and platelets.
AADACL1 Regulates RAP1 and PKC Activation
Having established that AADACL1 regulates allbb3 using com-
plementary pharmacologic and genetic methods, we searched
for a molecular mechanism by probing the two major signaling
nodes essential for aIIbb3 activation in platelets, RAP1 and
PKC. We treated platelets with AADACL1 inhibitors and first
examined the activation status of RAP1, a small molecular
weight GTPase crucial for inside-out signaling downstream of
collagen receptor signaling (Chrzanowska-Wodnicka et al.,
2005; Wang et al., 2009). Increasing concentrations of either
WWL91 (Figure 5A) or JW480 (Figure 5B) potently blocked
RAP1 activation in response to collagen at concentrations similar
to the IC50 for JW480-dependent inhibition of aggregation.
PKC activation is the second major node responsible for
aIIbb3 activation in platelets (Cifuni et al., 2008; Stefanini et al.,
2009). As with RAP1, JW480 blocked PKC activation in response
to collagen (Figure 5C). Phosphorylation of PKCa itself was
strongly reduced by JW480 at concentrations as low as 5 mM4, September 19, 2013 ª2013 Elsevier Ltd All rights reserved 1129
Figure 4. Genetic Disruption of AADACL1 in
CMK11-5 Cells Decreases allbb3 Activation
CMK11-5 cells were transfectedwith 50 nM siRNA
for 24 hr and differentiated with PMA as described
in Experimental Procedures.
(A) AADACL1 expression was genetically reduced
(knockdown) as detected by a monoclonal anti-
body as described (Chiang et al., 2006). Numbers
indicate relative expression levels of AADACL1
normalized to a PP2A loading control across four
experiments (94 ± 1% knockdown of AADACL1).
(B) Surface expression of allbb3 and GPVI did not
change upon siRNA treatment. Shown are repre-
sentative histograms of allbb3 and GPVI as
detected by flow cytometry on differentiated
CMK11-5 cells transfected with control or anti-
AADACL1 siRNA.
(C) AADACL1 protein levels were reduced as in (A)
and Fg binding to differentiated CMK11-5 cells
was measured (see Experimental Procedures).
AADACL1 knockdown significantly decreased Fg
binding to allbb3 (*p = 0.03, means ± SEM, n = 5) in
response to 5 mg/ml convulxin. RGD (1 mM) and
eptifibatide (10 mM) blocked Fg binding by 82%–
86% and 79%–86%, respectively, demonstrating that Fg binding is allbb3-dependent (*p < 0.03 for eptifibatide, **p < 0.003 for RGD). Knockdown was evaluated
from the same batch of cells used for every Fg binding experiment.
(D) Differentiated CMK11-5 cells were treated with 10 mM JW480 for 24 hr before measurement of Fg binding as described previously. JW480 significantly in-
hibited Fg binding by nearly 50% (*p < 0.04, means ± SEM, n = 3).
See also Figure S4.
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AADACL1 Promotes Platelet Activationand the PKC substrate pleckstrin also showed reduced phos-
phorylation in JW480-treated platelets (Figure 5D). Interestingly,
the phosphorylation of other PKC substrates was only partially
diminished by JW480, suggesting that not all PKC isoforms are
sensitive to JW480 or that PKC activity was only partially
inhibited. Thus, JW480 inhibits RAP1and PKC activation down-
stream of collagen receptors, which correlates with the aggrega-
tion defects noted earlier.
AADACL1 Regulates Ether Lipid Metabolism in Platelets
AADACL1 hydrolyzes the ether lipid substrate, 1-O-hexadecyl-
2-O-acetyl-sn-glycerol or HAG (general term is 2-acetyl monoal-
kylglycerol ether or 2-acetyl MAGE), in human cancer cells
(Chiang et al., 2006). To further understand the mechanism of
AADACL1 action in human platelets, we asked whether platelets
possess the same HAG hydrolase activity attributed to
AADACL1 in cancer cells. We found that human platelets contain
a comparable level of HAG hydrolase activity compared to
mouse brain extracts, which served as a positive control (Fig-
ure 6A). Pretreatment of resting platelets with JW480 dramati-
cally inhibited HAG hydrolase activity at concentrations that
block HAG hydrolysis in brain extracts, which demonstrates
that AADACL1 is the predominant HAG metabolizing enzyme
in these cells. We next measured endogenous levels of MAGE
lipids—known products of 2-acetyl MAGE hydrolysis in resting
and collagen-stimulated platelets. JW480-treated platelets
showed a 68%–80% decrease in the amounts of C16, C18,
and C18:1 MAGE lipids relative to DMSO-treated controls (Fig-
ure 6B). Collagen stimulated the production of C16MAGE, which
could be blocked by JW480 (Figure 6C). Thus, platelet AADACL1
exhibits a similar, if not identical, hydrolase activity found in other
tissues including invasive human cancer cells. Moreover, the
levels of endogenous MAGE lipids appear to be generated1130 Chemistry & Biology 20, 1125–1134, September 19, 2013 ª201primarily by AADACL1 hydrolase activity in the presence and
absence of the platelet agonist collagen.
Ether Lipids Inhibit Platelet Aggregation
The AADACL1 substrate, HAG, is known to exist in platelets and
can exert potent biologic activities on other hematopoietic cells
via direct inhibition of PKC isoforms through competition with
diacylglycerol (DAG) cofactors (Lee et al., 1990; Cabot and
Jaken, 1984; Mandal et al., 1997; Daniel et al., 1988). Therefore,
we reasoned that blockade of HAG hydrolysis by inhibiting
AADACL1may result in accumulation or stabilization of lipid sub-
strates like HAG that inhibit PKC activity and subsequent platelet
activation. To test this hypothesis, we analyzed the ability of HAG
to inhibit collagen-induced platelet aggregation. HAG inhibited
platelet aggregation in a dose-dependent manner with an IC50
of 12 mMwith a maximum inhibition of 88% at 50 mM (Figure 6D).
Interestingly, the addition of MAGE to platelets treated with
JW480 did not rescue platelet aggregation (Figure S5), suggest-
ing that AADACL1 substrates and not their obligatory products
are potential causative agents of platelet inhibition. These data
are consistent with a role for AADACL1 inmetabolizing ether lipid
substrates that act as endogenous, naturally occurring inhibitors
of platelet activation.
DISCUSSION
We used a chemoproteomic approach combining carbamate
profiling and competitive ABPP to screen human platelets and
identify different enzyme targets. This approach identified two
serine hydrolases, AADACL1 and APEH, which have not been
linked to human platelets. Using additional carbamates that
block AADACL1, a triazole urea compound specific for
APEH, and RNA interference, we show that AADACL1 is the3 Elsevier Ltd All rights reserved
Figure 5. AADACL1 Inhibitors Block RAP1 and PKC Activation
(A–D) Platelets were pretreated with the indicated concentrations of WWL91
(A) or JW480 (B) for 30 min and then stimulated with 10 mg/ml collagen (A) or
2 mg/ml collagen (B) for 10 min before lysis and measurement of RAP1-GTP
(activated RAP1). In (B)–(D), 10 mM eptifibatide was also added to prevent
outside-in signaling via allbb3. Total RAP1 served as a loading control. (C)
Activated PKC was analyzed with a polyclonal antibody that recognizes serine
phosphorylated substrates of PKC using the same conditions as in (B): lane 1
(0.5% DMSO, no agonist), lane 2 (0.5% DMSO and 2 mg/ml collagen), lane 3
(5 mM JW480 plus collagen), lane 4 (10 mM JW480 plus collagen), and lane 5
(20 mM JW480 plus collagen). Arrows indicate proteins phosphorylated on
PKC-consensus sites in a collagen-dependent manner that were decreased in
the presence of JW480. Blots were stripped and reblotted for PKCa to assess
protein loading. (D) Platelets from different donors were treated as in (C) (lanes
1–5). A serine-phosphorylated protein was detected at 47 kDa (upper) in
platelet lysates with the same antibody used in (C). Samples were also probed
with an antipleckstrin antibody to confirm pleckstrin identity and to assess
protein loading (bottom).
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stimulated platelets. Moreover, we propose that AADACL1 is a
potential drug target for antiplatelet therapy based on reasons
outlined subsequently.
AADACL1 regulates important prothrombotic signaling path-
ways downstream of the physiologic platelet agonists, collagen,
thrombin, and TxA2. These agonists are clinically relevant,
because collagen is a major component of atherosclerotic
plaques that triggers thrombosis, thrombin is essential for hemo-
stasis, and TxA2 production is blocked by aspirin. Inhibition of
these agonist-induced pathways is reversible since increasing
concentrations of agonist can completely overcome the effects
of the AADACL1-specific carbamate JW480 and restore platelet
aggregation. Thus, like other platelet regulators such as RAP1
and its exchange factor CALDAG GEFI, AADACL1 promotes
agonist signaling predominantly at low agonist concentrations
when signal amplification is required to activate platelets.
While our data clearly point to a role for AADACL1 in normal
platelet activation, a more pathologically relevant situation is
the regulation of thrombus formation. In an ex vivo thrombusChemistry & Biology 20, 1125–113formation assay using an arterial shear rate, inhibition of
AADACL1 with a relatively low dose of JW480 significantly
reduced the number of platelets incorporating into thrombi
without altering adhesion to immobilized collagen. The presence
of thrombi under these conditions demonstrates that, as with
aggregation, inhibition of AADACL1 does not completely block
collagen signaling and implies that higher amounts of collagen
would result in relatively normal thrombi. A higher concentration
of JW480, however, blocked thrombus formation more
completely, resulting in a platelet monolayer that resembled
the phenotype observed with eptifibatide. That inhibition of
AADACL1 mimics blockade of aIIbb3 by eptifibatide, a US
Food and Drug Administration-approved antithrombotic drug,
validates AADACL1 as a potential candidate target for anti-
platelet therapy.
Carbamates such as JW480 inhibit the lipid deacetylase
activity of AADACL1, which removes acetyl groups from ether
lipids including 1-O-hexadecyl-2-O-acetyl-sn-glycerol (HAG)
(Chiang et al., 2006). Our studies with JW480 demonstrate that
AADACL1 also hydrolyzes HAG to its corresponding monoalkyl-
glycerol ether (C16 MAGE) in human platelets, providing
evidence that AADACL1 regulates ether lipid metabolism in
platelets. HAG and the related ether lipid 1-O-hexadecyl-2-O-
methyl-glycerol (HMG) exert a variety of effects on other hemato-
poietic cell types including inhibition of growth, reduction of
antimicrobial processes, and promotion of differentiation
(Kramer et al., 1989; McNamara et al., 1984). Multiple investiga-
tors have also shown that HAG directly inhibits PKC activity by
competing with diacylglycerol (DAG) binding to the N-terminal
C1 domain (Daniel et al., 1988; Mandal et al., 1997; Tao et al.,
2009). PKC inhibition requires an alkyl linkage at the sn-1 posi-
tion of the lipid, because various hydrocarbon chain lengths,
degrees of saturation, or types of linkages at the sn-2 position
do not affect the ability of these ether lipids to block DAG-medi-
ated PKC activation. Consistent with this, we show that PKC
activity is reduced but not completely absent in platelets treated
with JW480 and that exogenous HAG dose-dependently inhibits
platelet aggregation to collagen. These data suggest that HAGor
related ether lipidsmetabolized by AADACL1 act as endogenous
inhibitors of signal transduction pathways and may represent a
physiologically relevant mechanism to limit platelet activation
in response to agonists such as collagen (Figure 7).
In addition to HAG, cholesterol esters (CE) have been reported
to be AADACL1 substrates in mouse macrophages, but this
substrate assignment is controversial and complicated by the
expression of several potentially redundant CE hydrolases in
macrophages (Buchebner et al., 2010; Sekiya et al., 2009).
AADACL1 does not hydrolyze abundant phospholipids such
as phosphatidylcholine or the bioactive ether lipid platelet-
activating factor (Chiang et al., 2006). Therefore, 2-acetyl
MAGE is the only undisputed physiologic substrate for
AADACL1, but even so, it may not totally account for the inhibi-
tory effects of WWL91 or JW480 in platelets.
SIGNIFICANCE
Human platelets are crucial mediators of the physiologic
balance between hemostatic processes that control blood
loss and thrombotic diseases such as heart attack and4, September 19, 2013 ª2013 Elsevier Ltd All rights reserved 1131
Figure 6. AADACL1 Inhibition Disrupts
Ether Lipid Metabolism in Platelets
(A) Platelets were treated with the indicated con-
centrations of JW480 or 0.5% DMSO for 30 min
before lysis and evaluation of AADACL1 activity.
HAG hydrolysis (pmol/106 cells) was measured in
human platelets in parallel with mouse brain
extracts using exogenous HAG substrate (Chang
et al., 2011). JW480 treatment inhibited HAG
hydrolysis by 90 ± 0.56% (2 mM), 90 ± 0.85%
(5 mM), and 91 ± 0.69% (10 mM). Shown is a
representative experiment (**p < 0.001, n = 3).
(B) Platelet C16, C18, and C18:1MAGE lipids were
assayed using a metabolomics approach in the
presence or absence of 20 mM JW480. JW480
lowered levels of C16, C18, and C18:1 MAGE by
67 ± 3.8%, 76 ± 7.6%, and 80 ± 7.6%, respec-
tively. MAGE levels were normalized to DMSO-
treated controls: each value from JW480-treated
samples was divided by its corresponding DMSO
control from the same donor to generate ‘‘% con-
trol’’ values, which are independent of other con-
trols. These values were depicted as means ±
SEM for all donors (only C16 control is shown,
**p < < 0.001, n = 4).
(C) C16 MAGE levels were measured by triple
quadrupoleMS in DMSO- or collagen-treated platelets. Platelets were treatedwith 10 mMJW480 or 0.1%DMSO for 2 hr, stimulatedwith 10 mg/ml collagen or not,
and lipids were extracted for MAGE quantitation (*p < 0.003 for DMSO black bars, **p < < 0.0001 for black and gray collagen bars, means ± SEM, n = 5).
(D) HAG was directly incubated with platelets for 30 min before the addition of 2 mg/ml collagen to induce aggregation. HAG significantly blocked platelet
aggregation in a dose-dependent manner compared to ethanol vehicle (0 HAG). Maximum inhibition was 88 ± 5.1% for 50 mM HAG (*p = 0.001, **p < < 0.001,
means ± SEM, n = 4).
See also Figure S5.
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consisting of phenotypic screening and competitive ABPP
to rapidly identify inhibitory carbamate compounds and their
respective molecular targets in human platelets. We
identified several inhibitors of human platelet activation
including WWL91, a chlorinated phenyl carbamate that
may represent a lead compound for the future development
of more selective and potent antiplatelet agents. We also
identified the major pharmacologic target of WWL91 as
AADACL1, a fundamental discovery that will likely drive
future investigations. We demonstrated systematically that
AADACL1 is an ether lipid deacetylase in platelets required
for signaling to the aIIbb3 integrin. Because this enzyme
appears to superimpose a previously unrecognized mecha-
nism of regulation downstream of many but not all platelet
agonists, AADACL1 represents a potential drug target.
An effective anti-AADACL1 drug would limit thrombosis
by blocking distinct signaling pathways not involved in
thrombin-dependent hemostasis and thus minimize the
risk of spontaneous bleeding. In conclusion, our finding of
AADACL1 in human platelets highlights the multilayered
complexity of platelet signaling networks and affords an
opportunity to explore the therapeutic potential of this
enzyme in thrombosis. More generally, our combination of
carbamate and activity-based protein profiling offers a
powerful strategy for identifying small molecule inhibitors
and their corresponding endogenous targets that may be
applicable to a range of critical cellular and biochemical
processes.1132 Chemistry & Biology 20, 1125–1134, September 19, 2013 ª201EXPERIMENTAL PROCEDURES
Carbamate Profiling
A small library of 120 carbamates (Li et al., 2007), JW480 (Chang et al.,
2011), or DMSO vehicle control was incubated in duplicate with quiescent
platelets (1 3 106) in HEPES-Tyrode’s buffer containing 1 mM CaCl2 for
30 min. Platelets were then treated with an agonist cocktail containing
15 mg/ml Alexa Fluor 647-Fg, 20 mg/ml FITC-P-selectin antibody (clone
AK-4), and various agonists including 10 mM thrombin receptor activating
peptide (TRAP) or 95 nM to 1 mM g-thrombin for 30 min. Fg binding and
P-selectin staining are shown as mean fluorescence intensities normalized
to the positive control (i.e., no carbamate) set at 100%. Normalization was
performed by dividing experimental fluorescence values by positive control
fluorescence. For Fg binding assays with JW480, Fg and AK-4 were added
separately. No agonist and DMSO vehicle controls containing Fg and AK-4
were included to measure background fluorescence. All reactions were per-
formed at room temperature (RT). Reactions were stopped with 5- to 10-fold
dilutions in HEPES-Tyrode’s buffer and immediately subjected to two-color
flow cytometry on a BD FACSCanto dual laser flow cytometer. Spectral
overlap was automatically compensated before data acquisition and data
was evaluated using mean fluorescence intensities (MFI) from duplicate
samples.Competitive ABPP
Competitive ABPP was performed with FP-biotin as described previously
(Chang et al., 2011). Briefly, platelets were treated with 0.25% DMSO or
25 mM carbamate for 30 min at RT and snap-frozen. Pellets were resuspended
in PBS, lysed, and 1 mg of human platelet lysate was treated with 5 mM
FP-biotin for 1 hr at RT. Unreacted probe was removed with a PD10 column
and the lysate was treated with 0.5% SDS and heated. FP-biotin binding
proteins were enriched using avidin affinity chromatography, reduced with
TCEP, alkylated with iodoacetamide, and digested with trypsin overnight.
The resulting peptides were analyzed with high-resolution MudPIT featuring3 Elsevier Ltd All rights reserved
Figure 7. AADACL1 Regulation of Agonist Signaling in Human
Platelets
Agonist binding to immunoglobulin-like and G protein-coupled receptors
stimulates intracellular calcium release and DAG production. These second
messengers activate RAP1 and PKC, which ultimately convert allbb3 from a
resting to an active conformation capable of binding Fg and promoting
aggregation. AADACL1 hydrolyzes endogenous ether-linked lipids such as
HAG that can compete for DAG binding to PKC, which may initiate and/or
sustain PKC activation in response to agonists. Carbamates, such as WWL91
or JW480, prevent AADACL1-dependent lipid hydrolysis and sensitize PKC to
inhibitory ether-linked competitors of DAG. JW480 also inhibits RAP1 activa-
tion through an unknown mechanism (dashed line). Therefore, AADACL1
metabolizes inhibitory ether lipids in platelets to maintain an optimal signaling
flux, especially at low doses of agonist that require amplification through
positive feedback loops.
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AADACL1 Promotes Platelet Activationa Thermo Scientific LTQ Orbitrap Velos mass spectrometer. Enzymes were
identified by searching public databases with the SEQUEST algorithm.
Differentiation and RNA Interference of CMK11-5 Cells
Human megakaryocyte-like CMK11-5 cells were purchased from the Health
Sciences Research Resources Bank in Japan and grown in RPMI, 10% fetal
bovine serum (FBS; growth media) at 37C with 5% CO2. Differentiation of
CMK11-5 cells was improved by a two-step process. First, cells were plated
at a density of 2 3 106 cells/well in six-well plates in growth media plus
160 nM phorbol myristate acetate (PMA) for 48 hr. Second, nonadherent cells
were removed by aspiration and media was changed to Iscove’s modified
Dulbecco’s medium (IMDM), 10% FBS plus PMA for 5 days to achieve
improved agonist responsiveness and high levels of allbb3.
RNAi-mediated AADACL1 knockdown was achieved during CMK11-5 dif-
ferentiation with 50 nM siRNA. Control siRNAs were derived from a mouse
R-Ras coding sequence or a nontargeting control sequence (Dharmacon).
Knockdown of AADACL1 was routinely greater than 90% as detected withChemistry & Biology 20, 1125–113western blotting with the monoclonal antibody 16C8. Loading was confirmed
with an anti-protein phosphatase 2A antibody (PP2A, clone 46). Band inten-
sities were quantitated with ImageJ software.
Flow Chamber Assay
Washed human platelets were treated with the indicated concentrations of
JW480, labeledwith calcein green (2.5mg/ml 10min), diluted to%33108 plate-
lets/ml andmixedwithmouse blood that wasmade thrombocytopenic by intra-
venous injection of antibodies against the human IL-4 receptor (hIL4Ra) into
transgenic mice (Kanaji et al., 2002). Reconstituted blood was immediately
perfused over collagen-coated chambers (200 mg/ml) at a shear rate of
1,600 s1 using a continuous flow syringe pump and adhesion of human plate-
lets was demonstrated on a Nikon TE300 microscope equipped with a QImag-
ingRetigaExiCCDcamera. Imageswere acquiredandanalyzedwithSlidebook
software. At each time point, fluorescence volume intensities were normalized
to the maximum value observed for the DMSO control. All human and mouse
blood was obtained using approved protocols from appropriate committees
at the University of North Carolina at Chapel Hill (IRB and IACUC, respectively).
Platelet Isolation and Aggregation Assays
Platelet experiments were performed as described in Supplemental Experi-
mental Procedures.
RAP1 and PKC Activation Assays
RAP1 activation was detected essentially as described with minor modifica-
tions (Wang et al., 2009). Gel-purified platelets were adjusted to 3 3 108/ml in
HEPES-Tyrode’s buffer in the absence of calcium and pretreated with 0.25%
DMSO or the indicated concentrations of carbamate for 30 min at RT in the
presence of 10 mM eptifibatide to prevent outside-in signaling. Platelets were
stimulated with various concentrations of agonist for 10 min and lysed with
cold 23 lysis buffer (20 mM HEPES pH 7.4, 150 mM NaCl, 10 mM CHAPS,
5 mMMgCl2, 5% glycerol, 1 mM Na3VO4, 1 mM NaF, and protease inhibitors).
Lysateswere probedwith RalGDS-RBDandprocessed as inWang et al., 2009.
GTP-bound and total RAP1 were detected via western blotting with a mono-
clonal or polyclonal antibody (clone 3, BD Biosciences or sc-65, Santa Cruz).
PKC activation was examined in the same platelet lysates used for RAP1
detection above. Phosphorylated substrates of PKC were detected with a
polyclonal anti-phosphoserine PKC substrate antibody (#2261, Cell Signaling
Technology). These blots were stripped and reblotted with a polyclonal anti-
PKCa (#2056, Cell Signaling Technology) or pleckstrin (clone 25, BD Biosci-
ences) antibody to verify protein loading.
Statistics
Data are presented as means ± SEM. Statistical significance was evaluated
using unpaired t tests and a 0.05 confidence limit for all experiments.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.chembiol.2013.07.011.
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